Skip to main content
main-content
Erschienen in: Allergo Journal 6/2016

26.09.2016 | Übersicht

Concepts and perspectives on peptide-based immunotherapy in allergy

verfasst von: Elena Tonti, PhD Mark Larché

Erschienen in: Allergo Journal | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Allergen-specific T cells play a key role in the pathogenesis of allergic diseases through provision of help for allergen-specific B cells and control of inflammatory responses. Allergen immunotherapy using intact allergen proteins (given either subcutaneously or sublingually) is clinically effective and demonstrates enduring efficacy (i. e., disease modifying). However, the requirement for monthly injections or daily sublingual administration (both for 3 years), combined with a high frequency of local and systemic adverse events, results in poor compliance. Targeting allergen-specific T cells with synthetic peptides representing dominant T cell epitopes markedly decreases treatment times (4–8 intradermal injections), reduces adverse events and provides efficacy for at least 2 years. We have developed peptide immunotherapies for allergies triggered by cats, house dust mites, and grass pollen.
Literatur
1.
Zurück zum Zitat Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993; 90:7608–12 CrossRefPubMedPubMedCentral Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993; 90:7608–12 CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Hoyne GF, O’Hehir RE, Wraith DC, Thomas WR, Lamb J. R. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993;178:1783–8 CrossRefPubMed Hoyne GF, O’Hehir RE, Wraith DC, Thomas WR, Lamb J. R. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993;178:1783–8 CrossRefPubMed
3.
Zurück zum Zitat Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z et al. Treatment of cat allergy with T-cell reactive peptides. Am I Respir Crit Care Med 1996;154:1623–8 CrossRef Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z et al. Treatment of cat allergy with T-cell reactive peptides. Am I Respir Crit Care Med 1996;154:1623–8 CrossRef
4.
Zurück zum Zitat Haselden BM, Kay AB, Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999 Jun 21;189:1885–94 CrossRefPubMedPubMedCentral Haselden BM, Kay AB, Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999 Jun 21;189:1885–94 CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat imons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:1937–45 CrossRef imons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:1937–45 CrossRef
6.
Zurück zum Zitat Pène J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF, et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998;102:571–8 CrossRefPubMed Pène J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF, et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998;102:571–8 CrossRefPubMed
7.
Zurück zum Zitat Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999;93:222–31 CrossRefPubMed Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999;93:222–31 CrossRefPubMed
8.
Zurück zum Zitat Creticos PS, Hebert J, Philip G and the Allervax® Ragweed Study Group. Efficacy of Allervax® ragweed in the treatment of ragweed-induced allergy. J Allergy Clin Immunol 1997;99:S401 CrossRef Creticos PS, Hebert J, Philip G and the Allervax® Ragweed Study Group. Efficacy of Allervax® ragweed in the treatment of ragweed-induced allergy. J Allergy Clin Immunol 1997;99:S401 CrossRef
9.
Zurück zum Zitat Muller U, Akdis C, Fricker M, Akdis M, Blesken T, Bettens F, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A, induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747–54 CrossRefPubMed Muller U, Akdis C, Fricker M, Akdis M, Blesken T, Bettens F, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A, induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747–54 CrossRefPubMed
10.
Zurück zum Zitat Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006;36:465–74 CrossRefPubMed Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006;36:465–74 CrossRefPubMed
11.
Zurück zum Zitat Oldfield WL, Kay AB, Larché M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001;167:1734–9 CrossRefPubMed Oldfield WL, Kay AB, Larché M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001;167:1734–9 CrossRefPubMed
12.
Zurück zum Zitat Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:47–53 CrossRefPubMed Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:47–53 CrossRefPubMed
13.
Zurück zum Zitat Alexander C, Tarzi M, Larché M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy. 2005 Oct;60:1269–74 CrossRefPubMed Alexander C, Tarzi M, Larché M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy. 2005 Oct;60:1269–74 CrossRefPubMed
14.
Zurück zum Zitat Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004;101 Suppl 2:14677–82 CrossRefPubMedPubMedCentral Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004;101 Suppl 2:14677–82 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003;111:854–61 CrossRefPubMed Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003;111:854–61 CrossRefPubMed
16.
Zurück zum Zitat Spertini F, Perrin Y, Audran R, Pellaton C, Boudousquié C, Barbier N, et al. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol. 2014;134:239–240.e13 CrossRefPubMed Spertini F, Perrin Y, Audran R, Pellaton C, Boudousquié C, Barbier N, et al. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol. 2014;134:239–240.e13 CrossRefPubMed
17.
Zurück zum Zitat Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011;127:89–97, 97.e1-14 CrossRefPubMed Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011;127:89–97, 97.e1-14 CrossRefPubMed
18.
Zurück zum Zitat Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs 2013;22:1347–57 CrossRefPubMed Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs 2013;22:1347–57 CrossRefPubMed
19.
Zurück zum Zitat Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larche M, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. Journal of Allergy and Clinical Immunology 2013;131:103–7 CrossRefPubMed Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larche M, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. Journal of Allergy and Clinical Immunology 2013;131:103–7 CrossRefPubMed
20.
Zurück zum Zitat Couroux P, Patel D, Armstrong K, Larche M, Hafner R. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 2015;45:974–81 CrossRefPubMed Couroux P, Patel D, Armstrong K, Larche M, Hafner R. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 2015;45:974–81 CrossRefPubMed
21.
Zurück zum Zitat Larche M, Hickey P, Hebert J, Hafner R. Safety and Tolerability of Escalating Doses of House Dust Mite-Peptide Antigen Desensitization (HDM-PAD) J Allergy Clin Immunol 2013;131:Supplement:AB37–135 CrossRef Larche M, Hickey P, Hebert J, Hafner R. Safety and Tolerability of Escalating Doses of House Dust Mite-Peptide Antigen Desensitization (HDM-PAD) J Allergy Clin Immunol 2013;131:Supplement:AB37–135 CrossRef
22.
Zurück zum Zitat Hafner R, Couroux P, Armstrong K, Salapatek AM, Patel D, Larche M, et al. Persistent treatment effect achieved at one year after four doses of Der p derived synthetic peptide immuno-regulatory epitopes in an exposure chamber model of House Dust Mite allergy. J Allergy Clin Immunol 2014;133:AB289–998 CrossRef Hafner R, Couroux P, Armstrong K, Salapatek AM, Patel D, Larche M, et al. Persistent treatment effect achieved at one year after four doses of Der p derived synthetic peptide immuno-regulatory epitopes in an exposure chamber model of House Dust Mite allergy. J Allergy Clin Immunol 2014;133:AB289–998 CrossRef
23.
Zurück zum Zitat Hafner RP, Salapatek AM, Larché M, Ahenkorah B, Patel P, Pawsey S. Comparison of the treatment effect of house dust mite synthetic peptides immune-regulatory epitopes in the environmental exposure chamber and field setting two years after a short course of treatment. Allergy 2015; 70 Supplement: 28 Hafner RP, Salapatek AM, Larché M, Ahenkorah B, Patel P, Pawsey S. Comparison of the treatment effect of house dust mite synthetic peptides immune-regulatory epitopes in the environmental exposure chamber and field setting two years after a short course of treatment. Allergy 2015; 70 Supplement: 28
24.
Zurück zum Zitat Pawsey S, Patel D, Hafner R, Hickey P, Powell J. Safety of House Dust Mite synthetic peptide immuno-regulatory epitopes in patients with House Dust Mite allergy and controlled asthma. J Allergy Clin Immunol 2015;135:AB142–461 CrossRef Pawsey S, Patel D, Hafner R, Hickey P, Powell J. Safety of House Dust Mite synthetic peptide immuno-regulatory epitopes in patients with House Dust Mite allergy and controlled asthma. J Allergy Clin Immunol 2015;135:AB142–461 CrossRef
25.
Zurück zum Zitat Ellis AK, Frankish CW, O’Hehir RE, Armstrong K, Steacy L, Larché M et al. Treatment with grass allergen peptides improves symptoms of grass pollen induced allergic rhinoconjunctivitis. J Allergy Clin Immunol 2016 (submitted) Ellis AK, Frankish CW, O’Hehir RE, Armstrong K, Steacy L, Larché M et al. Treatment with grass allergen peptides improves symptoms of grass pollen induced allergic rhinoconjunctivitis. J Allergy Clin Immunol 2016 (submitted)
26.
Zurück zum Zitat Hafner R, Salapatek AM, Patel D, Larche M, Laidler P. Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: the clinical benefits of treatment with Amb a 1 derived T cell epitopes. J Allergy Clin Immunol 2012;129:AB368–L16 CrossRef Hafner R, Salapatek AM, Patel D, Larche M, Laidler P. Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: the clinical benefits of treatment with Amb a 1 derived T cell epitopes. J Allergy Clin Immunol 2012;129:AB368–L16 CrossRef
27.
Zurück zum Zitat Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761–71 CrossRefPubMed Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761–71 CrossRefPubMed
28.
Zurück zum Zitat Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111:1255–61 CrossRefPubMed Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111:1255–61 CrossRefPubMed
29.
Zurück zum Zitat Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008;121:1120–1125.e2 CrossRefPubMed Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008;121:1120–1125.e2 CrossRefPubMed
30.
31.
Zurück zum Zitat Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med. 1993;178:2123–30 CrossRefPubMed Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med. 1993;178:2123–30 CrossRefPubMed
32.
Zurück zum Zitat Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993;92:644–51 CrossRefPubMedPubMedCentral Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993;92:644–51 CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009;206:1535–47 CrossRefPubMedPubMedCentral Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009;206:1535–47 CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Verhoef A, Alexander C, Kay AB, Larché M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005;2:e78 CrossRefPubMedPubMedCentral Verhoef A, Alexander C, Kay AB, Larché M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005;2:e78 CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Alexander C, Ying S, B Kay A, Larché M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005;35:52–8 CrossRefPubMed Alexander C, Ying S, B Kay A, Larché M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005;35:52–8 CrossRefPubMed
36.
Zurück zum Zitat Moldaver DM, Bharhani MS, Wattie JN, Ellis R, Neighbour H, Lloyd CM, et al. Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35. Mucosal Immunol 2014;7:379–90 CrossRefPubMed Moldaver DM, Bharhani MS, Wattie JN, Ellis R, Neighbour H, Lloyd CM, et al. Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35. Mucosal Immunol 2014;7:379–90 CrossRefPubMed
Metadaten
Titel
Concepts and perspectives on peptide-based immunotherapy in allergy
verfasst von
Elena Tonti
PhD Mark Larché
Publikationsdatum
26.09.2016
Verlag
Springer Medizin
Erschienen in
Allergo Journal / Ausgabe 6/2016
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-016-1169-8

Weitere Artikel der Ausgabe 6/2016

Allergo Journal 6/2016 Zur Ausgabe

AeDA/DGAKI informieren

Der AeDA fragt nach

Neu im Fachgebiet HNO

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update HNO und bleiben Sie gut informiert – ganz bequem per eMail.